Impact of Early Aging and Menopause on the Vascular Responses to Hypoxia
NCT ID: NCT06417177
Last Updated: 2025-09-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
EARLY_PHASE1
75 participants
INTERVENTIONAL
2024-06-03
2026-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sympathetic Vascular Transduction Across the Menopause Transition: Contributing Mechanisms
NCT06787066
A Randomized, Double Blind, Placebo Controlled, Clinical Study to Examine the Benefits of an Oral Product in Panelists With Menopausal Symptoms Including Vasomotor Symptoms (VMS).
NCT07033013
Hormone Replacement and Neural Cardiovascular Control in Postmenopausal Women
NCT01633814
Vasomotor Symptoms (VMS) Progesterone Study: Vasomotor Symptoms and Endothelial Function - Trial of Oral Micronized Progesterone
NCT00152438
Phytoserms for Menopause Symptoms and Age-Associated Memory Decline
NCT01723917
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hypoxia
Participants will be exposed to hypoxia (low oxygen air) using a mask.
Placebo
Participants will receive a placebo in pill form.
Propranolol
Participants will receive oral propranolol (1 mg/kg).
Gemtesa
Participants will receive oral gemtesa (75 mg).
Cold pressor test
Participants will be exposed to the cold pressor test (ice water on the foot).
Placebo
Participants will receive a placebo in pill form.
Propranolol
Participants will receive oral propranolol (1 mg/kg).
Gemtesa
Participants will receive oral gemtesa (75 mg).
Hypercapnia
Participants will be exposed to hypercapnia (high carbon dioxide air) using a mask.
Placebo
Participants will receive a placebo in pill form.
Propranolol
Participants will receive oral propranolol (1 mg/kg).
Gemtesa
Participants will receive oral gemtesa (75 mg).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Participants will receive a placebo in pill form.
Propranolol
Participants will receive oral propranolol (1 mg/kg).
Gemtesa
Participants will receive oral gemtesa (75 mg).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Pre, peri- or post-menopausal
* Healthy weight (BMI ≥18 and ≤30 kg/m2)
Exclusion Criteria
* Pregnancy, breastfeeding
* Use of hormone replacement therapies
* Hysterectomy
* Body mass index \>30 kg/m2
* Diagnosed sleep apnea
* Current smoking/Nicotine/Drug use
* Nerve/neurologic disease
* Cardiovascular, hepatic, renal, respiratory disease
* Blood pressure ≥140/90 mmHg
* Diabetes, Polycystic ovarian syndrome
* Communication barriers
* Prescription medications
* Malignant cancer
18 Years
70 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Missouri-Columbia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jacqueline K Limberg, PhD
Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Missouri-Columbia
Columbia, Missouri, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2100208
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.